Feed RWE.WA
RW

RWE Aktiengesellschaft RWE.WA · WSE

259.50 zł -0.19% (-0.50 zł)

Summary

61 / 100 · Bulios Score

What speaks for it

  • Out of every 100 EUR of revenue, 21 EUR is left as net profit.
  • Analysts expect revenue to grow by 10% this fiscal year.

What to watch

  • Revenue fell by 23% a year over the last 3 years.
  • The share price is above the Bulios Fair Price.
  • Operating profit covers the interest on its debt only 1.2 times.
  • It reports a profit, yet spends more cash than it brings in.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Current price 259.5 zł
Diversified Utilities industry median
P/E today 13.8

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 13.8 EUR for 1 EUR of yearly profit.

Valuation in detail

Is it growing?

Slowly

Revenue (EUR)

Diluted EPS (EUR)

  • Analyst estimate

Revenue grew by 5.2% a year over 5 years. Over the last 3 years it fell by 23% a year. For the next fiscal year analysts expect revenue to grow by 10%. Earnings per share grew by 3.1% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 EUR of revenue goes

Net profit, industry median (Diversified Utilities) 5.9 EUR

Out of every 100 EUR of revenue, 21 EUR is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.

Financial health in detail

Does it pay a dividend?

Small, at risk
Yield
1.96%
Paid out of profit
27%
Raised in a row
2 years

You receive 5.08 zł per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.